Cargando…
Remarkable Synergy When Combining EZH2 Inhibitors with YM155 Is H3K27me3-Independent
SIMPLE SUMMARY: Systems biology analysis of gene expression across solid tumors identifies a 27 signature that centers on EZH2, the key component of polycomb repressive complex 2. Our study demonstrates that targeting the 27 gene network by the combination of BIRC5 and EZH2 inhibitors achieves remar...
Autores principales: | Yang, Jun, Davidoff, Andrew M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818370/ https://www.ncbi.nlm.nih.gov/pubmed/36612203 http://dx.doi.org/10.3390/cancers15010208 |
Ejemplares similares
-
EZH2/H3K27Me3 and phosphorylated EZH2 predict chemotherapy response and prognosis in ovarian cancer
por: Sun, Si, et al.
Publicado: (2020) -
YM155 Inhibits NleB and SseK Arginine Glycosyltransferase Activity
por: Zhu, Congrui, et al.
Publicado: (2021) -
EZH2-mediated H3K27me3 inhibits ACE2 expression
por: Li, Yuanyuan, et al.
Publicado: (2020) -
EZH2-Mediated H3K27me3 Targets Transcriptional Circuits of Neuronal Differentiation
por: Buontempo, Serena, et al.
Publicado: (2022) -
YM155 Induces EGFR Suppression in Pancreatic Cancer Cells
por: Na, Young-Soon, et al.
Publicado: (2012)